MedTrace Logo

Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

NCT06764680 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-08-24

No results posted yet for this study

Summary

The current phase 2, double cohort clinical trial was designed to determine the effectiveness of Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab with/without involved lesions irradiation as 3rd- or later-line therapy for advanced MSS/pMMR colorectal cancer.

Conditions

  • Colorectal Cancer Metastatic
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiotherapy, Intensity-Modulated

Interventions

DRUG

Trifluorouracil tepidopyrimidine

30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w

DRUG

Bevacizumab

5mg/kg. ivgtt. d1 and d15. q4w

DRUG

Sindilizumab

200mg. ivgtt. d1. q4w

RADIATION

IMRT

In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Weiwei Xiao, M.D. · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06764680 on ClinicalTrials.gov